Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics

BACKGROUND: Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and late stage breast cancer. However, clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilken, Jason A, Webster, Kristy T, Maihle, Nita J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861058/
https://www.ncbi.nlm.nih.gov/pubmed/20346177
http://dx.doi.org/10.1186/1757-2215-3-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861058/
https://www.ncbi.nlm.nih.gov/pubmed/20346177
http://dx.doi.org/10.1186/1757-2215-3-7

Ejemplares similares